
## Ying Zhang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2512377/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study. International Journal of Endocrinology, 2022, 2022, 1-8.	1.5	4
2	Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Archives of Gynecology and Obstetrics, 2022, 306, 1711-1721.	1.7	10
3	Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment. Endocrine Journal, 2019, 66, 555-562.	1.6	17
4	Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. Diabetes Therapy, 2018, 9, 1945-1958.	2.5	20
5	Serum levels of nesfatin-1 are increased in gestational diabetes mellitus. Gynecological Endocrinology, 2017, 33, 621-624.	1.7	18
6	Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naÃ <sup>-</sup> ve Asian patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 124, 48-56.	2.8	13
7	Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clinical Endocrinology, 2017, 87, 767-774.	2.4	75
8	Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women. Obesity Medicine, 2017, 7, 15-20.	0.9	18
9	Changes in serum adipocyte fatty acidâ€binding protein in women with gestational diabetes mellitus and normal pregnant women during mid†and late pregnancy. Journal of Diabetes Investigation, 2016, 7, 797-804.	2.4	45
10	Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes. Diabetology and Metabolic Syndrome, 2014, 6, 37.	2.7	10